Clinical Professor of Medicine, University Ariz College of Medicine
Hematology
Dr. Raymond Taetle, MD
|
|
Give Review
Raymond Taetle is an expert in the field of Hematology. He graduated from Northwestern University Feinberg School of Medicine. Northwestern University Feinberg School of Medicine is ranked 19/29 in Research/PrimaryCare. He has 5 awards "America's Top Doctors", "Top Doctors:Arizona State", "America's Top Doctors for Cancer", "Meaningful Use Stage 1 Certification" and "Fellow (FACP)". Raymond Taetle is a published doctor and has 101 publications published. The lastest was: 'Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.' Raymond Taetle is registered with Medicare and accepts Medicare payments.
Publications
- Graph models of oncogenesis with an application to melanoma.
- Chromosome abnormalities in malignant melanoma: clinical significance of nonrandom chromosome abnormalities in 206 cases.
- Chromosome abnormalities in ovarian adenoCarcinoma: III. Using breakpoint data to infer and test mathematical models for oncogenesis.
- Characterization of MGI 114 (HMAF) histiospecific toxicity in human tumor cell lines.
- Chromosome abnormalities in ovarian adenoCarcinoma: I. Nonrandom chromosome abnormalities from 244 cases.
- Frequent alterations of evolutionarily conserved regions of chromosome 1 in human malignant melanoma.
- Chromosome abnormalities in ovarian adenoCarcinoma: II. Prognostic impact of nonrandom chromosome abnormalities in 244 cases.
- Abnormalities in the p34cdc2-related PITSLRE protein kinase gene complex (CDC2L) on chromosome band 1p36 in melanoma.
- Limited erythropoietic response to combined treatment with recombinant human interleukin 3 and erythropoietin in myelodysplastic Syndrome.
- Detection of chromosome 6 abnormalities in melanoma cell lines by chromosome arm painting probes.
- Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.
- Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6.
- Efficacy of MGI 114 (6-hydroxymethylacylfulvene, HMAF) against the mdr1/gp170 metastatic MV522 lung Carcinoma xenograft.
- Treatment with low-dose oral etoposide in patients with myelodysplastic Syndromes.
- Characterization of acylfulvene histiospecific toxicity in human tumor cell lines.
- Stimulation of hematopoiesis by amifostine in patients with myelodysplastic Syndrome.
- Increased chromosome 20 copy number detected by fluorescence in Situ hybridization (FISH) in malignant melanoma.
- Band 1p36 abnormalities and t(1;17) in ovarian Carcinoma.
- Characterization of cellular accumulation and toxicity of illudin S in sensitive and nonsensitive tumor cells.
- Expression of the Zn finger gene, EVI-1, in Acute promyelocytic leukemia.
- Clinical implications of cytogenetic abnormalities in melanoma.
- Expression of the zinc finger gene EVI-1 in ovarian and other Cancers.
- Efficacy of HMAF (MGI-114) in the MV522 metastatic lung carcinoma xenograft model nonresponsive to traditional antiCancer agents.
- Iron deprivation increases erythropoietin production in vitro, in normal subjects and patients with malignancy.
- (Hydroxymethyl)acylfulvene: an illudin derivative with superior antitumor properties.
- Amplification of 19q13.1-q13.2 sequences in ovarian Cancer. G-band, FISH, and molecular studies.
- Acylfulvenes, a new class of potent antitumor agents.
- Expression of the EVI1 gene in chronic myelogenous Leukemia in blast crisis.
- Effects of transforming growth factor beta 1 on growth and apoptosis of human Acute myelogenous leukemia cells.
- Retroviral gene transfer of epidermal growth factor receptor into HL60 cells results in a partial block of retinoic acid-induced granulocytic differentiation.
- Clonal chromosome abnormalities in 54 cases of ovarian Carcinoma.
- Effects of combined antigrowth factor receptor treatment on in vitro growth of multiple myeloma.
- High-dose carboplatin chemotherapy with GM-CSF and peripheral blood progenitor cell support: a model for deLivering repeated cycles of dose-intensive therapy.
- Characterization of illudin S sensitivity in DNA repair-deficient Chinese hamster cells. Unusually high sensitivity of ERCC2 and ERCC3 DNA helicase-deficient mutants i...
- Expression of EVI1 in myelodysplastic Syndromes and other hematologic malignancies without 3q26 translocations.
- In vitro and in vivo studies on the antiCancer activity of dehydroilludin M.
- Nonresponsiveness of the metastatic human lung carcinoma MV522 xenograft to conventional antiCancer agents.
- Chromosome microdissection identifies cryptic sites of DNA sequence amplification in human ovarian Carcinoma.
- Efficacy of Acylfulvene Illudin analogues against a metastatic lung carcinoma MV522 xenograft nonresponsive to traditional antiCancer agents: retention of activity aga...
- Simple numeric abnormalities as primary karyotype changes in ovarian Carcinoma.
- Mast cell growth factor (c-kit ligand) restores growth of multipotent progenitors in myelodysplastic Syndrome.
- Reinfusion and serial measurements of carboplatin-mobilized peripheral-blood progenitor cells in patients receiving multiple cycles of high-dose chemotherapy.
- Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate.
- In vitro growth and drug sensitivity of tumor colony-forming units from human tumor xenografts.
- An emerging role for prostaGlandin E1 in regulation of granulopoiesis.
- Effect of sodium thiosulfate on cis-dichlorodiammineplatinum(II) toxicity and antitumor activity in L1210 Leukemia.
- Colony-forming assay for circulating chronic lymphocytic Leukemia cells.
- Modulation of 5-fluorouracil toxicity by allopurinol in man.
- Acidic isoferritins (leukemia-associated inhibitory activity) fail to inhibit blast proliferation in Acute myelogenous leukemia.
- Abnormal modulation of granulocyte/macrophage progenitor proliferation by prostaGlandin E in chronic myeloproliferative disorders.
- Human T-cell antigens defined by monoclonal antibodies. Absence of T65 on committed Myeloid and erythroid progenitors.
- Thymidine as a chemotherapeutic agent: sensitivity of normal human marrow, peripheral blood T cells, and Acute nonlymphocytic leukemia.
- Comparison of the activity of doxorubicin Analogues using colony-forming assays and human xenografts.
- Modulation of leukaemia blast colony growth by steroid hormones.
- In vitro evidence for an unusual progenitor cell in Acute monocytic leukemia.
- Preclinical re-evaluation of benzaldehyde as a chemotherapeutic agent.
- Characterization of normal peripheral blood lymphocyte colony-forming cells: cell cycle status, surface markers, and cellular growth requirements.
- In vitro sensitivity to steroid hormones and cytotoxic agents of normal and malignant lymphocyte colony-forming cells.
- Response of human myeloid Leukemia cells to various sources of colony-stimulating activity and phytohemagglutinin-conditioned medium.
- Further studies on mechanisms of abnormal prostaGlandin response by chronic myelogenous leukaemia granulocyte/macrophage progenitors.
- Failure of low-dose, total-body irradiation to augment combination chemotherapy in extensive-stage small cell Carcinoma of the lung.
- Effects of anti-transferrin receptor antibodies on growth of normal and malignant Myeloid cells.
- Non-cross-resistant chemotherapy and consolidation radiotherapy for small cell Carcinoma of the lung.
- Extensive disease small cell Carcinoma of the lung: trial of non-cross resistant chemotherapy and consolidation radiotherapy.
- Plasma calcitonin as a marker of disease activity in patients with small cell Carcinoma of the lung.
- Modulation of normal and abnormal Myeloid progenitor proliferation by cyclic nucleotides and PGE1.
- Thymidine and hypoxanthine requirements of normal and malignant human cells for protection against methotrexate cytotoxicity.
- Effects of cyclic nucleotides and prostaGlandins on normal and abnormal human myeloid progenitor proliferation.
- Effect of interferon on colony formation in culture by blast cell progenitors in Acute myeloblastic leukemia.
- Specific toxicity of 2-chlorodeoxyadenosine toward resting and proliferating human lymphocytes.
- In vitro drug testing using hemopoietic cells: goals and limitations.
- Heterogeneity of Ia antigen expression by proliferating nonlymphocytic Leukemia blast cells.
- Preclinical studies on the use of selective antibody-ricin conjugates in autologous bone marrow transplantation.
- Treatment of chronic myelomonocytic leukemia. Vincristine and prednisone therapy during symptomatic phase or after transformation to Acute leukemia.
- Modulation of the activity of PALA by dipyridamole.
- Effects of monoclonal anti-transferrin receptor antibodies on in vitro growth of human solid tumor cells.
- Use of nude mouse xenografts as preclinical drug screens: in vivo activity of established chemotherapeutic agents against melanoma and ovarian Carcinoma xenografts.
- [Interrelation between transferrin receptor expression and intracellular ferritin concentration in Leukemia cells and normal marrow cells].
- Use of nude mouse xenografts as preclinical drug screens. Further studies on in vitro growth of xenograft tumor colony-forming cells.
- Use of nude mouse xenografts as preclinical screens. Characterization of xenograft-derived melanoma cell lines.
- Monoclonal antibodies to purified ricin A-chain: production and properties.
- Effects of epidermal growth factor on transferrin receptor phosphorylation and surface expression in malignant epithelial cells.
- Induction of colony-stimulating factor response in Myeloid leukaemia cell lines.
- CSF-responsive bone marrow cells in liquid culture: characterization and screening applications.
- Regulation of transferrin receptor expression in myeloid Leukemia cells.
- Preclinical evaluation of illudins as antiCancer agents.
- Uridine pharmacokinetics in Cancer patients.
- Drug screening and biological Systems.
- Effects of insulin and insulin-like growth factor I on growth of human Leukemia cells in serum-free and protein-free medium.
- Effects of anti-epidermal growth factor (EGF) receptor antibodies and an anti-EGF receptor recombinant-ricin A chain immunoconjugate on growth of human cells.
- Objective criteria for in-vitro responses in human tumor colony-forming assays.
- Ricin binding and protein synthesis inhibition in human hematopoietic cell lines.
- Gamma-interferon modulates human monocyte/macrophage transferrin receptor expression.
- Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies.
- Transferrin modulation of colony stimulating factor elaboration by adherent blood and bone marrow cells.
- Transferrin receptor regulation is coupled to intracellular ferritin in proliferating and differentiating HL60 Leukemia cells.
- Role of transferrin, Fe, and transferrin receptors in myeloid Leukemia cell growth. Studies with an antitransferrin receptor monoclonal antibody.
- Combination iron depletion therapy.
- Cytokines in Chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions.
- Induction of c-fos by an anti-epidermal growth factor receptor monoclonal antibody.
Schools
Northwestern University The Feinberg School Of Medicine
UC San Diego
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anemia
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
- Aetna HMO
- Aetna Savings Plus of AZ
- Choice Plus POS II
- American Republic
- Amerihealth
- Blue Card PPO
- Cigna HMO
- Cigna PPO
- Great West Healthcare-Cigna PPO
- LocalPlus
- Open Access Plus
- Cofinity PPO
- Commercial Insurance Company
- CoreSource
- Emblem Health
- First Health (Coventry Health Care) PPO
- Golden Rule
- GEHA
- Health Net PPO
- Medicare Advantage PFFS
- HealthSmart
- Tucson HMOx
- Medicaid
- Medicare MCR
- MultiPlan PPO
- PHCS Network PPO
- Heritage Signature
- Choice Plus POS
- Options PPO
- United Healthcare
Awards
- America's Top Doctors
- Top Doctors:Arizona State
- America's Top Doctors for Cancer
- Meaningful Use Stage 1 Certification
- Fellow (FACP)
Education
-
University of California San Diego -
Northwestern University Feinberg School of Medicine
Hospital
-
TMC Healthcare
Drug Facts
| NPI NUMBER | 1326002411 | |
| NPPES Provider LastName | TAETLE | |
| NPPES Provider FirstName | RAYMOND | |
| NPPES Provider ZIPCode | 857103587 | |
| NPPES Provider State | AZ | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 514.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 22.0 | |
| Percent Opioid Claims | 4.28 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1326002411 |
| Last Name Of The Provider | TAETLE |
| First Name Of The Provider | RAYMOND |
| View All |
Similar Doctors
|
|
Dr. Daruka Mahadevan, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Emad Elquza, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel O. Persky, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rashad A. Aboul-Nasr, MD |
|
|
Dr. Gerald Altschuler, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Alison T. Stopeck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sarah G. McGinn, MD |
|
|
Dr. Catherine A. Azar, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher Disimone, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Quentin S. Ringenberg, MD |
|
|
Dr. Frederick R. Ahmann, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manuel Modiano, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lucas Redd, MD |
|
|
Dr. Natalie A. Swansen, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Shahram Mori, MD
This Doctor is OpenDoctor Recommended.
|